Skip to main content

Drug Interactions between aldesleukin and Sinografin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

aldesleukin iodipamide

Applies to: aldesleukin and Sinografin (diatrizoate / iodipamide)

MONITOR: An increased incidence (12.6%) of acute, atypical reactions to iodinated contrast media has been observed in patients who have been previously treated with interleukin-2. The cause and mechanism have not been established. Symptoms generally have an onset of 1 to 4 hours and may include nausea, vomiting, diarrhea, fever, chills, flu-like symptoms, joint pain, rash, pruritus, hypotension, edema, and oliguria. Reactions have typically been reported when patients received iodinated contrast media within 4 weeks after the last dose of interleukin-2, but have also occurred several months after interleukin treatment.

MANAGEMENT: Patients should be monitored for adverse reactions after receiving iodinated contrast media, and symptomatic treatment initiated as clinically appropriate.

References

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics PROD (2001):
  2. "Product Information. Ultravist (iopromide)." Berlex Laboratories PROD (2001):

Switch to consumer interaction data

Moderate

aldesleukin diatrizoate

Applies to: aldesleukin and Sinografin (diatrizoate / iodipamide)

MONITOR: An increased incidence (12.6%) of acute, atypical reactions to iodinated contrast media has been observed in patients who have been previously treated with interleukin-2. The cause and mechanism have not been established. Symptoms generally have an onset of 1 to 4 hours and may include nausea, vomiting, diarrhea, fever, chills, flu-like symptoms, joint pain, rash, pruritus, hypotension, edema, and oliguria. Reactions have typically been reported when patients received iodinated contrast media within 4 weeks after the last dose of interleukin-2, but have also occurred several months after interleukin treatment.

MANAGEMENT: Patients should be monitored for adverse reactions after receiving iodinated contrast media, and symptomatic treatment initiated as clinically appropriate.

References

  1. "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics PROD (2001):
  2. "Product Information. Ultravist (iopromide)." Berlex Laboratories PROD (2001):

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer